Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine plus TPO-RA in ANA-positive ITP
NCT06479291Recruiting
- Start
- Jul 2024
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Randomised, open-label trial of hydroxychloroquine in immune thrombocytopenia (ITP) (2 arms). Primary endpoint: Overall response rate at 4 weeks. Started Jul 2024; status: recruiting.
02
Drugs
hydroxychloroquine
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT06479291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06479291.